The Food and Drug Administration (FDA) has granted Orphan Drug designation to Surface Oncology’s lead investigational candidate SRF231, a potential treatment for patients with multiple myeloma.
SRF231 is a fully human monoclonal antibody therapeutic targeting CD47, a protein overexpressed on many cancer cells which prevents them from being engulfed and eliminated by macrophage mediated phagocytosis.
The treatment is currently being examined in a dose escalation Phase 1 trial to establish a recommended dose for further study and to also assess safety and tolerability. Following this, the Company plans to evaluate SRF231 in a targeted set of solid and hematologic malignancies.
“We have already demonstrated the ability of our antibody to increase phagocytosis of myeloma cells and to shrink tumors in preclinical models,” said Rob Ross, MD, chief medical officer of Surface Oncology. “Receiving Orphan designation for SRF231 represents an important milestone as we continue to progress the program in the clinic in multiple myeloma and other cancer types.”
For more information visit Surfaceoncology.com.
This article originally appeared on MPR